Abstract
The article defines the role of a combination of several acquired thrombogenic risk factors with Activated Protein C (APC) resistance which is due to carriage of FVL (1691)GA genotype to develop Venous Thromboembolic Complications (VTEC). In this regard, a prospective clinical study of 1100 women of reproductive age was conducted. The patients were divided into two groups. The main group–500 patients with FVL (1691)GA genotype, and the control group–600 women with FVL(1691)GG genotype. Based on the findings of the conducted study, it was concluded that carriage of FVL (1691)GA genotype is associated with VTEC development compared to the normozygous genotype. The highest incidence of primary thrombotic events was identified on the background of combined hormonal contraceptive administration. In the event of VTEC, carriers of Factor V Leiden (FVL (1691)GA) mutation often suffer from hypertensive disorders, varicose disease of the lower extremities, overweight and/or combinations of these pathology types. It was defined that in all cases of thrombosis episode, the value of APC resistance was ≤ 0.49 according to Normalized Ratio (NR), while episodes of VTEC were not observed in NR ≥ 0.5.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Hematology & Thromboembolic Diseases
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
